Chiesi USA Partners with Durham Bulls to Donate $15,000 to Three Triangle Nonprofits
October 03, 2022 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based specialty pharmaceutical company, felt like part of the team as the company concluded its presenting strikeout...
Chiesi is Recertified as a B Corp and Sets New Tougher Objectives for Action by 2025
September 22, 2022 11:45 ET
|
Chiesi USA, Inc.
The Group has increased its B Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019The recertification process by B Lab identifies further focus for action and...
Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars Program
September 06, 2022 09:10 ET
|
Chiesi USA, Inc.
Chiesi USA sponsored the innovative ASHP Foundation Pharmacy Leadership Scholars program, awarding $50,000 in grants to five early-stage pharmacist researchers CARY, N.C., Sept. 06, 2022 ...
Chiesi Group joins White House pledge to decarbonize healthcare sector
July 25, 2022 09:00 ET
|
Chiesi USA, Inc.
Chiesi Group signed the HHS Health Care Sector Climate Pledge to achieve even greater progress on climate resilienceThe White House cited Chiesi’s leadership in exceeding the pledge by tackling...
Chiesi tracks actions taken for a healthier, more sustainable future
July 14, 2022 09:00 ET
|
Chiesi USA, Inc.
Chiesi’s Annual and Sustainability Report 2021 is released today;Progress toward business, environmental and social targets is strong;Company is joining forces with all stakeholders to advance...
Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice
June 01, 2022 09:00 ET
|
Chiesi USA, Inc.
The CAMEO registry, an ongoing study to provide real-world data on KENGREAL® (cangrelor), has published interim results in the Journal of the American Heart Association.This analysis from CAMEO is the...
Chiesi Group Continues to Grow In 2021
April 11, 2022 09:00 ET
|
Chiesi USA, Inc.
Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6%Growth across global markets, with U.S. up more than 10% and China up 22%Continued focus on innovation: Chiesi invests...
Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021
March 16, 2022 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $815,000 in 2021 through its Chiesi in the Community...
Chiesi USA certified as a Great Place to Work® in 2021
February 24, 2022 09:00 ET
|
Chiesi USA, Inc.
Employee-led assessment affirms Chiesi USA’s strong performance in culture, leadership, values and trust CARY, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based...
Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk
January 25, 2022 09:00 ET
|
Chiesi USA, Inc.
Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor)...